Publications
"CHANGE POINT ANALYSIS OF HISTONE MODIFICATIONS REVEALS EPIGENETIC BLOCKS LINKING TO PHYSICAL DOMAINS." Ann Appl Stat 10, no. 1 (2016): 506-526.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
"Bayesian inference on risk differences: an application to multivariate meta-analysis of adverse events in clinical trials." Stat Biopharm Res 5, no. 2 (2013): 142-155.
"Composite large margin classifiers with latent subclasses for heterogeneous biomedical data." Stat Anal Data Min 9, no. 2 (2016): 75-88.
"Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration." Biometrics 71, no. 4 (2015): 918-28.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"Estimating individualized treatment rules for ordinal treatments." Biometrics 74, no. 3 (2018): 924-933.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
"Targeted Local Support Vector Machine for Age-Dependent Classification." J Am Stat Assoc 109, no. 507 (2014): 1174-1187.
"Sparse and Efficient Estimation for Partial Spline Models with Increasing Dimension." Ann Inst Stat Math 67, no. 1 (2015): 93-127.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Joint modeling of survival time and longitudinal outcomes with flexible random effects." Lifetime Data Anal 24, no. 1 (2018): 126-152.
"Joint Analysis of Survival Time and Longitudinal Categorical Outcomes." Stat Biosci 7, no. 1 (2015): 19-47.
"Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the Dirichlet process prior." Br J Math Stat Psychol 64, no. Pt 1 (2011): 69-106.
"Fitting Nonlinear Ordinary Differential Equation Models with Random Effects and Unknown Initial Conditions Using the Stochastic Approximation Expectation-Maximization (SAEM) Algorithm." Psychometrika 81, no. 1 (2016): 102-34.
"Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk." Stat Methods Med Res 21, no. 6 (2012): 621-33.
"Bivariate random effects meta-analysis of diagnostic studies using generalized linear mixed models." Med Decis Making 30, no. 4 (2010): 499-508.
"Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis." Influenza Other Respir Viruses 6, no. 2 (2012): 80-6.
"Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy." Clin Pharmacol Ther 108, no. 3 (2020): 625-634.
"Partial likelihood estimation of isotonic proportional hazards models." Biometrika 105, no. 1 (2018): 133-148.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
JMDesign: Statistical design for joint models of longitudinal and survival data (R).. v1.1 ed., 2012.
"Regression Models on Riemannian Symmetric Spaces." J R Stat Soc Series B Stat Methodol 79, no. 2 (2017): 463-482.
"FSR Methods for Second-Order Regression Models." Comput Stat Data Anal 55, no. 6 (2011): 2026-2037.
"Generation of a Transcriptional Radiation Exposure Signature in Human Blood Using Long-Read Nanopore Sequencing." Radiat Res 193, no. 2 (2020): 143-154.
"Tree based weighted learning for estimating individualized treatment rules with censored data." Electron J Stat 11, no. 2 (2017): 3927-3953.
"Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed." Lifetime Data Anal 19, no. 4 (2013): 513-46.
"FEATURE ELIMINATION IN KERNEL MACHINES IN MODERATELY HIGH DIMENSIONS." Ann Stat 47, no. 1 (2019): 497-526.
"A Powerful Test for SNP Effects on Multivariate Binary Outcomes using Kernel Machine Regression." Stat Biosci 10, no. 1 (2018): 117-138.
Optimal dynamic treatment regimes In Wiley Statsref. Optimal dynamic treatment regimes., 2016.
"Value search estimators for optimal dynamic treatment regimes." In Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine, 135-155. Philadelphia: ASA-SIAM, 2016.
"Dynamic treatment regimes." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016.
"Bayesian Transformation Models for Multivariate Survival Data." Scand Stat Theory Appl 41, no. 1 (2014): 187-199.
"Bayesian frailty models for multi-state survival data." In Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. New York: Springer, 2016.
"A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309.
"Bayesian path specific frailty models for multi-state survival data with applications." Biometrics 71, no. 3 (2015): 760-71.
"Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
"Superiority of combining two independent trials in interim futility analysis." Stat Methods Med Res 29, no. 2 (2020): 522-540.
"Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
"Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
"Efficient methods for signal detection from correlated adverse events in clinical trials." Biometrics 75, no. 3 (2019): 1000-1008.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Ascertaining properties of weighting in the estimation of optimal treatment regimes under monotone missingness." Stat Med 39, no. 25 (2020): 3503-3520.
BayesCTDesign: Two Arm Bayesian Clinical Trial Design with and Without Historical Control Data (R)., 2018.
"Bayesian clinical trial design using Markov models with applications to autoimmune disease." Contemp Clin Trials 63 (2017): 73-83.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Sequential advantage selection for optimal treatment regime." Ann Appl Stat 10, no. 1 (2016): 32-53.
"Concordance-Assisted Learning for Estimating Optimal Individualized Treatment Regimes." J R Stat Soc Series B Stat Methodol 79, no. 5 (2017): 1565-1582.
"Change-Plane Analysis for Subgroup Detection and Sample Size Calculation." J Am Stat Assoc 112, no. 518 (2017): 769-778.
"Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology 5, no. 7 (2016): e1172153.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Adaptively weighted large-margin angle-based classifiers." J Multivar Anal 166 (2018): 282-299.
"Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
"Semiparametric estimation of the accelerated failure time model with partly interval-censored data." Biometrics 73, no. 4 (2017): 1161-1168.
Power calculations and confidence intervals in phase II design with over enrollment (SAS/R).., 2014.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"Multivariate network-level approach to detect interactions between large-scale functional systems." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 298-305.
"Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study." Stat Biosci 10, no. 2 (2018): 473-489.
"Semiparametric Regression Analysis of Multiple Right- and Interval-Censored Events." J Am Stat Assoc 114, no. 527 (2019): 1232-1240.
"Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy." Technol Cancer Res Treat 18 (2019): 1533033819849073.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"Cook's Distance Measures for Varying Coefficient Models with Functional Responses." Technometrics 57, no. 2 (2015): 268-280.
"A Model-Free Machine Learning Method for Risk Classification and Survival Probability Prediction." Stat 3, no. 1 (2014): 337-350.
"On optimal treatment regimes selection for mean survival time." Stat Med 34, no. 7 (2015): 1169-84.
"Endpoints for cancer clinical trials." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016.
"Design of phase III clinical trials." In Oncology Clinical Trials: Successful Design, Conduct, and Analysis. New York: Demos Medical Publishing, LLC, 2010.
Sorting the wheat from the chaff: How do we know which cancer therapies really work? . Huffington Post, 2013.
"Data fraud in clinical trials." Clin Investig (Lond) 5, no. 2 (2015): 161-173.
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis.. Boca Raton: Chapman & Hall / CRC Press, 2016.
"Targeted cancer clinical trials." In Designs for Clinical Trials, 157-177. New York: Springer, 2012.
"Failure time regression with continuous informative auxiliary covariates." J Stat Distrib Appl 2 (2015): 2.
"Unified Analysis of Secondary Traits in Case-Control Association Studies." J Am Stat Assoc 108, no. 502 (2013).
"Q-LEARNING WITH CENSORED DATA." Ann Stat 40, no. 1 (2012): 529-560.
"Adaptive Q-learning." In From Probability to Statistics and Back: High-Dimensional Models and Processes -- A Festschrift in Honor of Jon A. Wellner, 150-162. Vol. 9. Beachwood, Ohio: Institute of Mathematical Statistics, 2013.
"An Exponential Bound for Cox Regression." Stat Probab Lett 82, no. 7 (2012): 1267-1272.
"Comment on "Adaptive Confidence Intervals for the Test Error in Classification"." J Am Stat Assoc 106, no. 495 (2011): 920-924.
"Comment on "Dynamic treatment regimes: technical challenges and applications"." Electron J Stat 8, no. 1 (2014): 1290-1300.
"Efficient test-based variable selection for high-dimensional linear models." J Multivar Anal 166 (2018): 17-31.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.